| Literature DB >> 35987629 |
Abbas Alibakhshi1, Saman Sheikhi2, Seyed Mostafa Meshkati Yazd1, Ali Ardekani3, Keivan Ranjbar3,4, Reza Shahriarirad5,6.
Abstract
INTRODUCTION: In papillary thyroid cancer patients, the extent of dissection is still a matter of debate. Evaluating Delphian lymph nodes (DLNs) during the surgery has been speculated as a valuable tool to determine the extent of dissection. Herein, we aimed to evaluate the incidence and features of DLNs involvement in patients with papillary thyroid carcinoma.Entities:
Keywords: Delphian lymph node; Lymphatic metastasis; Papillary thyroid carcinoma; Sentinel lymph node
Mesh:
Year: 2022 PMID: 35987629 PMCID: PMC9392353 DOI: 10.1186/s12893-022-01742-5
Source DB: PubMed Journal: BMC Surg ISSN: 1471-2482 Impact factor: 2.030
Clinical features of patients with papillary tumor
| Variable | Total; N = 61 | Delphian lymph node involvement | P-value* | ||
|---|---|---|---|---|---|
| Positive; | Negative; | ||||
| Age (years); mean ± SD | 38.2 ± 12.0 | 39.2 ± 13.2 | 37.9 ± 11.7 | 0.743 | |
| Age group; n (%) | ≤ 30 | 22 (36.1) | 5 (38.5) | 17 (35.4) | 0.803 |
| 31–40 | 18 (29.5) | 3 (23.1) | 15 (31.3) | ||
| 41–50 | 10 (16.4) | 3 (23.1) | 7 (14.6) | ||
| 51–60 | 8 (13.1) | 1 (7.7) | 7 (14.6) | ||
| > 60 | 3 (4.9) | 1 (7.7) | 2 (4.2) | ||
| Gender; n (%) | Male | 16 (26.2) | 4 (30.8) | 12 (25.0) | 0.728 |
| Female | 45 (73.8) | 13 (69.2) | 36 (75.0) | ||
| Location of mass; n (%) | Right | 31 (50.8) | 8 (61.5) | 23 (47.9) | 0.240 |
| Left | 21 (34.4) | 1 (7.7) | 20 (41.7) | ||
| Bilateral | 9 (14.8) | 4 (30.8) | 5 (10.4) | ||
| Lymphatic involvement; n (%) | Same side of mass | 9 (14.8) | 8 (61.5) | 1 (2.1) | |
| The opposite side of mass | 4 (6.6) | 3 (23.1) | 1 (2.1) | ||
| Central lymph node | 15 (26.3) | 9 (69.2) | 6 (12.5) | ||
| Tumor size (centimeter); mean ± SD | 2.1 ± 1.6 (0.2–7.9) | 2.4 ± 1.3 | 2.0 ± 1.7 | 0.428 | |
| Tumor size group; n (%) | ≤ 1 cm | 17 (29.8) | 3 (27.3) | 14 (30.4) | 1.000 |
| > 1 cm | 40 (70.2) | 8 (72.7) | 32 (69.6) | ||
| Tumor characteristics; n (%) | Multifocal | 15 (24.6) | 6 (46.2) | 9 (18.8) | 0.067 |
| Vascular invasion | 23 (37.7) | 9 (69.2) | 14 (29.2) | ||
| Capsule invasion | 30 (49.2) | 6 (46.2) | 24 (50.0) | 0.806 | |
| Perineural invasion | 5 (8.2) | 1 (7.7) | 4 (8.3) | 1.000 | |
| Pathology; n (%) | Classical | 48 (78.7) | 12 (92.3) | 36 (75.0) | 0.875 |
| Follicular | 9 (14.8) | 1 (7.7) | 7 (16.7) | ||
| Medullary/papillary microcarcinoma | 1 (1.6) | 0 (0) | 1 (2.1) | ||
| Tall cell | 1 (1.6) | 0 (0) | 1 (2.1) | ||
| Tall cell and follicular | 1 (1.6) | 0 (0) | 1 (2.1) | ||
SD standard deviation
Bold value indicator of significant association
*Chi-square/Fisher’s exact test or independent sample t-test
The potency of Delphian lymph node involvements* in predicting other parts' involvements
| Same side of mass | Opposite side of mass | Central lymph node | Vascular invasion | |
|---|---|---|---|---|
| PPV | 8/13; 61.5% | 3/13; 23.1% | 9/13; 69.2% | 9/13; 69.2% |
| NPV | 47/48; 97.9% | 47/48; 97.9% | 42/48; 87.5% | 34/48; 70.8% |
| Sensitivity | 8/9; 88.9% | 3/4; 75.0% | 9/15; 60.0% | 9/23; 39.1% |
| Specificity | 47/52; 90.4% | 47/57, 82.5% | 42/46; 91.3% | 34/38; 89.5% |
PPV positive predictive value, NPV negative predictive value
*The values are calculated for significant findings